Gelonghui, April 18 | Guobang Pharmaceutical (605507.SH) announced that due to their own capital requirements, shareholders Zhejiang Minjin Henghua and Silk Road Fund plan to reduce their holdings of the company's total shares by no more than 16,764,705 shares through centralized bidding and bulk transactions, with a reduction ratio of no more than 3% of the company's total share capital.
国邦医药(605507.SH):浙民投恒华、丝路基金拟减持不超过3%股份
Guobang Pharmaceutical (605507.SH): Zhejiang Minjin Investment Henghua and Silk Road Fund plan to reduce their holdings by no more than 3%
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.